The glycosaminoglycan (GAG) class of carbohydrates is characterized by unparalleled sequence diversity. Located on the cell surface and in the extracellular matrix, specific structural features are required for a variety of functions including coagulation, cell-signaling and wound healing among others. One limitation to elucidating detailed structure-function relationships between GAGs and their binding partners is the absence of significant quantities of chemically pure GAG oligosaccharides.
The aims of this project are to: ? Provide an initial library oftetra-, hexa- and octasaccharide GAG sequences ? Develop a flexible synthetic strategy for producing multiple oligosaccharides from a single intermediate (Intermediate is defined as a chemical entity produced en route to a final product. In this case, the contractor plans to produce GAG building blocks, which shall" be modified in such a way as to generate more advanced chemical entities (intermediates), each of which can be used to produce multiple final products in the target library). ? Produce large quantities of GAG building blocks for use in the current proposal and in future libraries

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research – Phase I (N43)
Project #
261201300049C-0-0-1
Application #
8764549
Study Section
Project Start
2013-09-12
Project End
2014-06-11
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$299,248
Indirect Cost
Name
Ancora Pharmaceuticals, Inc.
Department
Type
DUNS #
130452118
City
Medford
State
MA
Country
United States
Zip Code
02155